Characteristics of 306 patients aged 40 y or older receiving RIC allogeneic HCT for CML, 2001 to 2007
| Characteristic . | 40-49 y, N (%) . | 50-59 y, N (%) . | ≥ 60 y, N (%) . | P . |
|---|---|---|---|---|
| No. of patients | 117 | 119 | 70 | |
| No. of centers | 65 | 67 | 42 | |
| Median age, y (range) | 44 (40-49) | 55 (50-59) | 63 (60-75) | < .0001 |
| Male sex | 62 (53) | 63 (53) | 42 (60) | .58 |
| Karnofsky score prior transplant ≥ 80% | 107 (91) | 97 (82) | 63 (90) | .17 |
| Missing | 4 (3) | 10 (8) | 2 (3) | |
| Prior autologous transplant | 1 (1) | 6 (5) | 1 (1) | .10 |
| Pre-HCTtherapy | ||||
| No imatinib | 29 | 36 | 14 | |
| Imatinib | 85 | 81 | 54 | |
| Missing | 3 | 2 | 2 | |
| Disease status at transplant | < .0001 | |||
| CP1 | 84 (72) | 52 (44) | 22 (31) | |
| AP/CP2 | 30 (26) | 56 (47) | 39 (56) | |
| BP | 3 (3) | 11 (9) | 9 (13) | |
| Interval from diagnosis to HCT, CP1 only | .37 | |||
| < 1 y | 29 (35) | 11 (21) | 7 (32) | |
| 1-2 y | 28 (33) | 20 (38) | 5 (23) | |
| ≥ 2 y | 27 (32) | 21 (40) | 10 (45) | |
| Donor | .05 | |||
| HLA-identical sibling | 65 (56) | 50 (42) | 28 (40) | |
| Unrelated donor | .09 | |||
| URD, well matched | 23 (20) | 36 (30) | 27 (39) | |
| URD, partially matched | 16 (14) | 19 (16) | 4 (6) | |
| URD, mismatched | 5 (4) | 5 (4) | 4 (6) | |
| URD, missing | 8 (7) | 9 (8) | 7 (10) | |
| Donor-recipient sex match | .72 | |||
| M-M | 34 (29) | 41 (34) | 28 (40) | |
| M-F | 30 (26) | 31 (26) | 13 (19) | |
| F-M | 28 (24) | 22 (18) | 14 (20) | |
| F-F | 25 (21) | 25 (21) | 15 (21) | |
| Donor-recipient CMV match | .66 | |||
| −/− | 25 (21) | 32 (27) | 19 (27) | |
| −/+ | 23 (20) | 30 (25) | 12 (17) | |
| +/+ | 53 (45) | 40 (34) | 32 (46) | |
| +/− | 13 (11) | 13 (11) | 5 (7) | |
| Unknown | 3 (3) | 4 (3) | 2 (3) | |
| Graft type | .10 | |||
| Bone marrow | 26 (22) | 24 (20) | 7 (10) | |
| Peripheral blood | 91 (78) | 95 (80) | 63 (90) | |
| Year of transplant | .12 | |||
| 2001-2004 | 77 (66) | 89 (75) | 43 (61) | |
| 2005-2007 | 40 (34) | 30 (25) | 27 (39) | |
| Conditioning regimen intensity | .46 | |||
| Reduced intensity | 91 (78) | 91 (76) | 49 (70) | |
| Nonmyeloablative | 26 (22) | 28 (24) | 21 (30) | |
| Conditioning regimen | .28 | |||
| TBI < 200 cGy | 14 (12) | 22 (18) | 15 (21) | |
| TBI ≥ 200 cGy | 5 (4) | 12 (10) | 4 (6) | |
| Alkylator only (Cy, Mel, Bu, Thio), no TBI | 93 (79) | 82 (69) | 49 (70) | |
| Other | 5 (4) | 3 (3) | 2 (3) | |
| GVHD prophylaxis | .97 | |||
| CsA ± MTX ± other | 46 (39) | 40 (34) | 28 (40) | |
| Tacrolimus ± MTX ± other | 19 (16) | 23 (10) | 12 (17) | |
| T-cell depletion or other | 52 (44) | 56 (47) | 30 (42) | |
| Median follow-up of survivors, mo | 45 (2-101) | 60 (2-105) | 37 (6-92) |
| Characteristic . | 40-49 y, N (%) . | 50-59 y, N (%) . | ≥ 60 y, N (%) . | P . |
|---|---|---|---|---|
| No. of patients | 117 | 119 | 70 | |
| No. of centers | 65 | 67 | 42 | |
| Median age, y (range) | 44 (40-49) | 55 (50-59) | 63 (60-75) | < .0001 |
| Male sex | 62 (53) | 63 (53) | 42 (60) | .58 |
| Karnofsky score prior transplant ≥ 80% | 107 (91) | 97 (82) | 63 (90) | .17 |
| Missing | 4 (3) | 10 (8) | 2 (3) | |
| Prior autologous transplant | 1 (1) | 6 (5) | 1 (1) | .10 |
| Pre-HCTtherapy | ||||
| No imatinib | 29 | 36 | 14 | |
| Imatinib | 85 | 81 | 54 | |
| Missing | 3 | 2 | 2 | |
| Disease status at transplant | < .0001 | |||
| CP1 | 84 (72) | 52 (44) | 22 (31) | |
| AP/CP2 | 30 (26) | 56 (47) | 39 (56) | |
| BP | 3 (3) | 11 (9) | 9 (13) | |
| Interval from diagnosis to HCT, CP1 only | .37 | |||
| < 1 y | 29 (35) | 11 (21) | 7 (32) | |
| 1-2 y | 28 (33) | 20 (38) | 5 (23) | |
| ≥ 2 y | 27 (32) | 21 (40) | 10 (45) | |
| Donor | .05 | |||
| HLA-identical sibling | 65 (56) | 50 (42) | 28 (40) | |
| Unrelated donor | .09 | |||
| URD, well matched | 23 (20) | 36 (30) | 27 (39) | |
| URD, partially matched | 16 (14) | 19 (16) | 4 (6) | |
| URD, mismatched | 5 (4) | 5 (4) | 4 (6) | |
| URD, missing | 8 (7) | 9 (8) | 7 (10) | |
| Donor-recipient sex match | .72 | |||
| M-M | 34 (29) | 41 (34) | 28 (40) | |
| M-F | 30 (26) | 31 (26) | 13 (19) | |
| F-M | 28 (24) | 22 (18) | 14 (20) | |
| F-F | 25 (21) | 25 (21) | 15 (21) | |
| Donor-recipient CMV match | .66 | |||
| −/− | 25 (21) | 32 (27) | 19 (27) | |
| −/+ | 23 (20) | 30 (25) | 12 (17) | |
| +/+ | 53 (45) | 40 (34) | 32 (46) | |
| +/− | 13 (11) | 13 (11) | 5 (7) | |
| Unknown | 3 (3) | 4 (3) | 2 (3) | |
| Graft type | .10 | |||
| Bone marrow | 26 (22) | 24 (20) | 7 (10) | |
| Peripheral blood | 91 (78) | 95 (80) | 63 (90) | |
| Year of transplant | .12 | |||
| 2001-2004 | 77 (66) | 89 (75) | 43 (61) | |
| 2005-2007 | 40 (34) | 30 (25) | 27 (39) | |
| Conditioning regimen intensity | .46 | |||
| Reduced intensity | 91 (78) | 91 (76) | 49 (70) | |
| Nonmyeloablative | 26 (22) | 28 (24) | 21 (30) | |
| Conditioning regimen | .28 | |||
| TBI < 200 cGy | 14 (12) | 22 (18) | 15 (21) | |
| TBI ≥ 200 cGy | 5 (4) | 12 (10) | 4 (6) | |
| Alkylator only (Cy, Mel, Bu, Thio), no TBI | 93 (79) | 82 (69) | 49 (70) | |
| Other | 5 (4) | 3 (3) | 2 (3) | |
| GVHD prophylaxis | .97 | |||
| CsA ± MTX ± other | 46 (39) | 40 (34) | 28 (40) | |
| Tacrolimus ± MTX ± other | 19 (16) | 23 (10) | 12 (17) | |
| T-cell depletion or other | 52 (44) | 56 (47) | 30 (42) | |
| Median follow-up of survivors, mo | 45 (2-101) | 60 (2-105) | 37 (6-92) |
Percentage with 3-y follow-up: age 40 to 49 y, 76%; 50 to 59 y, 87%; ≥ 60 y, 86%; and overall, 82%.
Cy indicates cyclophosphamide; Mel, melphalan; Bu, busulfan; Thio, thiotepa; CsA, cyclosporin A; MTX, methotrexate; M, male; and F, female.